A phase 1 study of durvalumab as monotherapy or combined with tremelimumab with or without azacitidine in patients with myelodysplastic syndrome.

Authors: Garcia-Manero, Guillermo, Gaddh, Manila, Platzbecker, Uwe, Lindsley, R. Coleman, Larson, Sarah M., Chevassut, Timothy, Fenaux, Pierre, Komrokji, Rami, Lyons, Roger, Al-Kali, Aref, Jiang, Yu, Bothos, John, Townsley, Danielle M., Zeidan, Amer M.

Source: Annals of Hematology; Mar2025, Vol. 104 Issue 3, p1577-1585, 9p

Subject Terms: MYELODYSPLASTIC syndromes, AZACITIDINE, ADVERSE health care events, QUANTITATIVE research, MYELOID-derived suppressor cells, CANCER treatment

Disease and Clinical Characteristics of Patients With a Clinical Diagnosis of Myelofibrosis Enrolled in the MOST Study

Authors: Gerds, Aaron T., Lyons, Roger M., Colucci, Philomena, Kalafut, Patricia, Paranagama, Dilan, Verstovsek, Srdan

Source: In Clinical Lymphoma, Myeloma and Leukemia July 2022 22(7):e532-e540

Disease and Clinical Characteristics of Patients With a Clinical Diagnosis of Essential Thrombocythemia Enrolled in the MOST Study

Authors: Yacoub, Abdulraheem, Lyons, Roger, Verstovsek, Srdan, Shao, Ryan, Chu, David Tin, Agrawal, Apurv, Sivaraman, Smitha, Colucci, Philomena, Paranagama, Dilan, Mascarenhas, John

Source: In Clinical Lymphoma, Myeloma and Leukemia July 2021 21(7):461-469

Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method

Authors: Cuker, Adam ^*, Despotovic, Jenny M., Grace, Rachael F., Kruse, Caroline, Lambert, Michele P., Liebman, Howard A., Lyons, Roger M., McCrae, Keith R., Pullarkat, Vinod, Wasser, Jeffrey S., Beenhouwer, David, Gibbs, Sarah N., Yermilov, Irina, Broder, Michael S.

Source: In Research and Practice in Thrombosis and Haemostasis January 2021 5(1):69-80

Characteristics, blood counts, treatments, and clinical outcomes of 5871 patients with polycythemia vera treated in US community practices.

Authors: Lyons, Roger M.¹ (AUTHOR) Roger.Lyons@usoncology.com, Aguilar, Kathleen M.² (AUTHOR), Sudharshan, Lavanya² (AUTHOR), Venkatasetty, Divea² (AUTHOR), Ndukum, Juliet² (AUTHOR), Zackon, Ira¹ (AUTHOR), Yu, Jingbo³ (AUTHOR)

Source: Current Medical Research & Opinion. Jan2025, Vol. 41 Issue 1, p43-51. 9p.

Subject Terms: *LEUKOCYTE count, *THROMBOSIS, *POLYCYTHEMIA vera, *ELECTRONIC health records, *BLOOD cells

Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib

Authors: Manda, Sudhir, Yimer, Habte A., Noga, Stephen J., Girnius, Saulius, Yasenchak, Christopher A., Charu, Veena, Lyons, Roger, Aiello, Jack, Bogard, Kimberly, Ferrari, Renda H., Cherepanov, Dasha, Demers, Brittany, Lu, Vickie, Whidden, Presley, Kambhampati, Suman, Birhiray, Ruemu E., Jhangiani, Haresh S., Boccia, Ralph, Rifkin, Robert M.

Source: In Clinical Lymphoma, Myeloma and Leukemia November 2020 20(11):e910-e925

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

Authors: Nicol, Andrew, Grigoriadis, George, Catalano, John, LeBlanc, Richard, Elemary, Mohamed, Bahlis, Nizar, Facon, Thierry, Karlin, Lionel, Ribrag, Vincent, Attal, Michel, Goldschmidt, Hartmut, Engelhardt, Monika, Weisel, Katja, Mackensen, Andreas, Nagler, Arnon, Ben Yehuda, Dina, Avivi, Irit, Benyamini, Noam, Magen-Nativ, Hila, Palumbo, Antonio, Cavo, Michele, Tobinai, Kensei, Iida, Shinsuke, Chou, Takaai, Suzuki, Kenshi, Kosugi, Hiroshi, Taniwaki, Masafumi, Sunami, Kazutaka, Matsumoto, Morio, Ando, Kiyoshi, Ganly, Peter, Blacklock, Hilary, Simpson, David, George, Anupkumar, Schjesvold, Fredrik, Gjertsen, Bjorn, Lahuerta, Juan, Blade, Joan, Oriol Rocafiguera, Albert, Mateos, Maria, Rodriguez-Otero, Paula, Larson, Sarah, Atanackovic, Djordje, Devarakonda, Srinivas, Bitran, Jacob, Zonder, Jeffrey, Morganstein, Neil, Hay, Mohammad, Chanan-Khan, Asher, Saylors, Gene, Kio, Ebenezer, Oliff, Ira, Kirkel, Dean, Shtivelband, Mikhail, Yuen, Carrie, Yee, Andrew, Shah, Jatin, Htut, Myo, Raza, Shahzad, Chhabra, Saurabh, Stiff, Patrick, Hari, Parameswaran, Bank, Bruce, Malek, Ehsan, Gasparetto, Cristina, Faroun, Ycaoub, Sherbenou, Daniel, Kreisle, William, Singhal, Seema, Rosenblatt, Jacalyn, Usmani, Saad, Lee, Wes, Safah, Hana, Lutzky, Jose, Suh, Jason, Pan, Dorothy, Baron, Ari, Manges, Robert, Steis, Ronald, Oliveira, Moacyr, Moreb, Jan, Callander, Natalie, Anz, Bertrand, Raptis, Anastasios, Stampleman, Laura, Melear, Jason, Boyd, Thomas, Garbo, Lawrence, Klein, Leonard, Shao, Spencer, Lyons, Roger, McIntyre, Kristi, Tarantolo, Stefano, Yasenchak, Christopher, Yimer, Habte, Mateos, Maria-Victoria ^*, Oriol, Albert, Larocca, Alessandra, Usmani, Saad Z, Jagannath, Sundar, Ocio, Enrique M, San Miguel, Jesus, Kher, Uma, Farooqui, Mohammed, Liao, Jason, Marinello, Patricia, Lonial, Sagar

Source: In The Lancet Haematology September 2019 6(9):e459-e469

Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Authors: Shah, Jatin, Usmani, Saad, Stadtmauer, Edward A., Rifkin, Robert M., Berenson, James R., Berdeja, Jesus G., Lyons, Roger M., Klippel, Zandra, Chang, Yu-Lin, Niesvizky, Ruben

Source: In Clinical Lymphoma, Myeloma and Leukemia September 2019 19(9):570-578

Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma

Authors: Leleu, Xavier, Martin, Thomas G., Einsele, Hermann, Lyons, Roger M., Durie, Brian G.M., Iskander, Karim S., Ailawadhi, Sikander

Source: In Clinical Lymphoma, Myeloma and Leukemia January 2019 19(1):9-22

MPN-186 Community Versus Academic Practice in Essential Thrombocythemia and Myelofibrosis: Differences in Clinical Characteristics, Diagnosis, Treatment Patterns, and Symptom Burden: Analysis of Data from the MOST Study

Authors: Lyons, Roger M. ¹, Lessen, David ², Fazal, Salman ³, Scherber, Robyn ⁴, Kalafut, Patricia ⁴, Ren, Haobo ⁴, Ritchie, Ellen ⁵

Source: In Clinical Lymphoma, Myeloma and Leukemia October 2022 22 Supplement 2:S329-S329

MPN-077 Characteristics, Blood Counts, Treatments, and Clinical Outcomes of 3022 Patients With Polycythemia Vera (PV) Treated in US Community Practices

Authors: Lyons, Roger M. ¹, Aguilar, Kathleen M. ², Sudharshan, Lavanya ², Venkatasetty, Divea ², Ndukum, Juliet ², Zackon, Ira ¹, Yu, Jingbo ³

Source: In Clinical Lymphoma, Myeloma and Leukemia October 2022 22 Supplement 2:S325-S325

MDS-476 Sabatolimab (MBG453) Combination Treatment Regimens for Patients With Higher-Risk Myelodysplastic Syndromes (HR-MDS): The Myelodysplastic Syndromes Studies in the STIMULUS Immuno-Myeloid Clinical Trial Program

Authors: Zeidan, Amer M. ¹, Al-Kali, Aref ², Borate, Uma ³, Cluzeau, Thomas ⁴, DeZern, Amy E. ⁵, Esteve, Jordi ⁶, Giagounidis, Aristoteles ⁷, Kobata, Krissy ⁸, Lyons, Roger ⁹, Platzbecker, Uwe ¹⁰, Sallman, David A. ¹¹, Santini, Valeria ¹², Sanz, Guillermo F. ¹³, Sekeres, Mikkael A. ¹⁴, Wei, Andrew H. ¹⁵, Xiao, Zhijian ¹⁶, Van Hoef, Marlies ¹⁷, Nourry-Boulot, Claire ¹⁷, Sadek, Islam ¹⁸, Ma, Fei ¹⁸, Iordan, Angelica ¹⁷, Sabo, John ¹⁸, Garcia-Manero, Guillermo ¹⁹

Source: In Clinical Lymphoma, Myeloma and Leukemia October 2022 22 Supplement 2:S317-S317

Easter ceremonies in Jerusalem.

Authors: Lyons, Roger.

Availability: https://www.aspresolver.com/aspresolver.asp?GLMU;72592

This result is not displayed to guests.
Login for full access.

Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: Registry analysis at 5 years

Authors: Lyons, Roger M., Marek, Billie J., Paley, Carole, Esposito, Jason, McNamara, Katie, Richards, Paul D., DiBella, Nicholas, Garcia-Manero, Guillermo

Source: In Leukemia Research May 2017 56:88-95

Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial

Authors: Raskob, Gary E, van Es, Nick, Segers, Annelise, Angchaisuksiri, Pantep, Oh, Doyeun, Boda, Zoltan, Lyons, Roger M, Meijer, Karina, Gudz, Ivan, Weitz, Jeffrey I, Zhang, George, Lanz, Hans, Mercuri, Michele F, Büller, Harry R

Source: In The Lancet Haematology August 2016 3(8):e379-e387

CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma

Authors: Berenson, James R., Cartmell, Alan, Bessudo, Alberto, Lyons, Roger M., Harb, Wael, Tzachanis, Dimitrios, Agajanian, Richy, Boccia, Ralph, Coleman, Morton, Moss, Robert A., Rifkin, Robert M., Patel, Priti, Dixon, Sandra, Ou, Ying, Anderl, Janet, Aggarwal, Sanjay, Berdeja, Jesus G.

Source: In Blood 30 June 2016 127(26):3360-3368

ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study.

Authors: Maris, Michael, Salles, Gilles, Kim, Won Seog, Kim, Tae Min, Lyons, Roger M., Arellano, Martha, Karmali, Reem, Schiller, Gary, Cull, Elizabeth, Abboud, Camille N., Batlevi, Connie, Kagiampakis, Ioannis, Rebelatto, Marlon C., Lee, Young, Kirby, Lyndon C., Wang, Fujun, Bothos, John, Townsley, Danielle M., Fathi, Amir T., Ribrag, Vincent

Source: Targeted Oncology; May2024, Vol. 19 Issue 3, p321-332, 12p

Efficacy and safety of ofatumumab and bendamustine followed by ofatumumab maintenance in patients with relapsed indolent non-Hodgkin lymphoma after prior rituximab.

Authors: Lyons, Roger M.^1,2 (AUTHOR), Shtivelband, Mikhail³ (AUTHOR), Kingsley, Edwin^2,3 (AUTHOR), Moezi, Mehdi⁴ (AUTHOR), Richards, Donald^2,5 (AUTHOR), Sharman, Jeff^2,6 (AUTHOR), Feng, Xiaoshu⁷ (AUTHOR), Cannan, Megan⁷ (AUTHOR), Fellague-Chebra, Rafik⁸ (AUTHOR), Boyd, Thomas E.⁹ (AUTHOR)

Source: Leukemia & Lymphoma. Jun2021, Vol. 62 Issue 6, p1353-1360. 8p.

Subject Terms: *NON-Hodgkin's lymphoma, *RITUXIMAB, *ADVERSE health care events

Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry

Authors: Lyons, Roger M., Marek, Billie J., Paley, Carole, Esposito, Jason, Garbo, Lawrence, DiBella, Nicholas, Garcia-Manero, Guillermo

Source: In Leukemia Research February 2014 38(2):149-154